Physician profile
Jo A Sparnall
NPI 1780612416
$1,028.94
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $110 · 2021: $241 · 2022: $345 · 2023: $198 · 2024: $24.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $222.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $163.29 | 2021-2023 | Vraylar |
| Novo Nordisk INC | $98.67 | 2019-2023 | Ozempic, Rybelsus |
| Neurocrine Biosciences, INC. | $95.95 | 2022-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $82.22 | 2022-2023 | Trintellix |
| Amgen INC. | $78.47 | 2019-2022 | |
| Abbott Laboratories | $70.82 | 2022-2024 | Freestyle Libre 3 |
| Pfizer INC. | $56.48 | 2019-2021 | |
| Edwards Lifesciences Corporation | $55.46 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $45.77 | 2022 | |
| Janssen Pharmaceuticals, INC | $42.09 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $38.92 | 2022-2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $34.54 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.22 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.53 | 2020-2021 | |
| Pulmonx Corporation | $17.52 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.41 | 2021 | |
| Amarin Pharma, INC. | $14.45 | 2020 | |
| Neos Therapeutics, LP | $13.97 | 2023 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $13.69 | 2023 | Xelstrym |
| Merck Sharp & Dohme LLC | $12.61 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jo Sparnall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.